| Customization: | Available |
|---|---|
| Product Name: | Lapatinib |
| CAS: | CAS 231277-92-2 |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Lapatinib |
| Appearance | Yellow powder |
| cas | 231277-92-2 |
| Assay | 99% |
| Shelf Life | 24 months when properly stored |
| Storage | Keep in a cool, dry, dark location |
Description:
Lapatinib, a new member of the 4-anilinoquinazoline class of RTK inhibitors (RTKIs), was launched as an oral treatment for breast cancer. Lapatinib has dual affinity for EGFR and HER2 tyrosine kinases. It is indicated in combination for treating patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy
Application:
Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
Hot sale Items:
){kind=link}